Acceleron Pharma Inc (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 19,000 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $42.89, for a total value of $814,910.00. Following the completion of the transaction, the chief financial officer now owns 45,300 shares of the company’s stock, valued at approximately $1,942,917. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Acceleron Pharma Inc (NASDAQ:XLRN) traded down $1.46 during midday trading on Thursday, hitting $42.94. The stock had a trading volume of 332,656 shares, compared to its average volume of 275,733. Acceleron Pharma Inc has a 1 year low of $23.07 and a 1 year high of $44.80. The stock has a market cap of $1,929.73, a PE ratio of -16.58 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.02. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.55) EPS. equities analysts predict that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.

XLRN has been the subject of a number of recent analyst reports. Credit Suisse Group set a $51.00 price objective on Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, November 14th. HC Wainwright started coverage on Acceleron Pharma in a research report on Thursday, October 12th. They set a “buy” rating and a $57.00 price target on the stock. Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Barclays upped their price target on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, September 20th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $44.56.

Institutional investors and hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP lifted its holdings in Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Acceleron Pharma by 969.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 3,288 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Acceleron Pharma during the 3rd quarter worth about $225,000. Trexquant Investment LP purchased a new stake in Acceleron Pharma during the 3rd quarter worth about $266,000. Finally, PNC Financial Services Group Inc. lifted its holdings in Acceleron Pharma by 57.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares in the last quarter. 85.70% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Kevin F. Mclaughlin Sells 19,000 Shares of Acceleron Pharma Inc (XLRN) Stock” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/04/kevin-f-mclaughlin-sells-19000-shares-of-acceleron-pharma-inc-xlrn-stock.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.